EASL International Liver Congress 2022
Jun 25, 2022 at 6:30 PM BST
Oral Presentation: Pemvidutide (ALT-801), a novel GLP-1/Glucagon Dual Receptor Agonist, Achieves Rapid and Potent Reductions in Body Weight and Liver Fat: Results of a Placebo-Controlled, Double-Blind, First-in-Human (FIH) Clinical Trial
Speaker: Stephen Harrison, M.D., Visiting Professor of Hepatology, Radcliffe Department of Medicine, University of Oxford and Medical Director for Pinnacle Clinical Research and the President of Summit Clinical Research in San Antonio, TX
